Publications by authors named "E Bauvin"
Background: With the increase in the number of long-term survivors, interest is shifting from cancer survival to life and quality of life after cancer. These include consequences of long-term side effects of treatment, such as gonadotoxicity. Fertility preservation is becoming increasingly important in cancer management.
View Article and Find Full Text PDFArticle Synopsis
- Too few women with invasive breast cancer are informed about the risk of hypofertility after chemotherapy, but gamete preservation can prevent this risk, and increased awareness could lead to higher acceptance rates.
- The study focuses on outlining the oncofertility care pathway and estimates that if all women were informed, a significant increase in gamete preservation would be seen, especially among younger women.
- Despite only 39% of participants being informed about hypofertility risks, the predictive model suggests that better communication could lead to a notable increase in gamete preservation, emphasizing the need for oncologists to inform younger patients.
Non-menopausal women with breast cancer treated with chemotherapy are at intermediate risk of post-treatment amenorrhea and decreased fertility. Although they should receive appropriate information, studies until now show that this is inadequate. We investigated the proportion of women who received information about this risk during the pre-treatment consultation, and those who received an oncofertility consultation to preserve their gametes.
View Article and Find Full Text PDFObjectives: We studied both the independent and combined effects of the places of biopsy and treatment on the treatment time interval based on a population-based study.
Methods: We analysed the proportion of patients having a treatment time interval higher than the EUSOMA recommendation of 6 weeks, as a function of the number and the type of care centres the patients attended, from a French population-based regional cohort of women treated in 2015 for an incident invasive non-metastatic cancer (n = 505).
Results: About 33% [95% CI: 27; 38] of patients had a treatment time interval higher than 6 weeks.